{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:55:26Z","timestamp":1771880126852,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.euroneuro.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:41:33Z","timestamp":1591915293000},"page":"60-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016"],"prefix":"10.1016","volume":"36","author":[{"given":"Michael","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.05.001_bib0001","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0002","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/bjp.bp.107.042853","article-title":"Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials","volume":"193","author":"\u00c1lvarez-Jim\u00e9nez","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2020.05.001_bib0003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","article-title":"Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotics-naive first-episode schizophrenia patients","volume":"65","author":"Arranz","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2020.05.001_bib0004","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0005","series-title":"Kompendium Der Psychiatrischen Pharmakotherapie. 11. Auflage","author":"Benkert","year":"2017"},{"issue":"8","key":"10.1016\/j.euroneuro.2020.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/oby.2008.277","article-title":"Adiposity and eating behaviors in patients under second generation antipsychotics","volume":"16","author":"Blouin","year":"2008","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.euroneuro.2020.05.001_bib0007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/0269881112473789","article-title":"Weight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database","volume":"27","author":"Bushe","year":"2013","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.05.001_bib0009","first-page":"32","article-title":"Case report: reversible metabolic syndrome under olanzapine","volume":"16","author":"Dabbert","year":"2009","journal-title":"Psychopharmakotherapie"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0010","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain. management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effect of antipsychotic medications on appetite, weight, and insuline resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol. Metab. Clin. N Am."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.05.001_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"De Silva","year":"2016","journal-title":"BMC Psychiatry 3"},{"issue":"2","key":"10.1016\/j.euroneuro.2020.05.001_bib0013","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0035-1552670","article-title":"Nichtpharmakologische interventionen zur pr\u00e4vention von gewichtszunahme bei schizophrenen patienten unter antipsychotischer medikation","volume":"42","author":"Fink","year":"2015","journal-title":"Psychiatr. Prax."},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40352-016-0037-7","article-title":"Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications","volume":"4","author":"Gates","year":"2016","journal-title":"Health Justice"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40345-016-0068-y","article-title":"Lithium side effects and toxicity: prevalence and management strategies","volume":"4","author":"Gitlin","year":"2016","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0018","article-title":"Pharmacotherapy of psychiatric inpatients with adjustment disorder from 2000 to 2016","author":"Greiner","year":"2019","journal-title":"Eur Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2020.05.001_bib0019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00406-013-0419-y","article-title":"Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study","volume":"264","author":"Grohmann","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2020.05.001_bib0020","first-page":"S4","article-title":"The AMSP drug safety program: methods and global results","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2020.05.001_bib0021","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","article-title":"Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study","volume":"3","author":"Gr\u00fcnder","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2020.05.001_bib0022","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","article-title":"Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians","volume":"124","author":"Hasnain","year":"2012","journal-title":"Postgrad. Med."},{"issue":"2","key":"10.1016\/j.euroneuro.2020.05.001_bib0023","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.euroneuro.2020.05.001_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/104012371702900205","article-title":"Minimizing weight gain for patients taking antipsychotic medications: the potential role for early use of metformin","volume":"29","author":"Hendrick","year":"2017","journal-title":"Ann. Clin. Psychiatry"},{"issue":"9618","key":"10.1016\/j.euroneuro.2020.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.euroneuro.2020.05.001_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00406-017-0820-z","article-title":"The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain","volume":"268","author":"Kanji","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.euroneuro.2020.05.001_bib0027","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"J. Clin. Psychopharmacol"},{"issue":"6","key":"10.1016\/j.euroneuro.2020.05.001_bib0028","doi-asserted-by":"crossref","first-page":"e759","DOI":"10.1038\/tp.2016.25","article-title":"Is increased antidepressant exposure a contributory factor to the obesity pandemic?","volume":"15","author":"Lee","year":"2016","journal-title":"Trans. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2020.05.001_bib0029","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl. J. Med."},{"issue":"2","key":"10.1016\/j.euroneuro.2020.05.001_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/acps.12445","article-title":"Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management","volume":"132","author":"Manu","year":"2015","journal-title":"Acta. Psychiatry Scand."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.05.001_bib0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2020.05.001_bib0032","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2020.05.001_bib0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the cafe study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2020.05.001_bib0034","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2020.05.001_bib0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"22","author":"Raben","year":"2018","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/j.euroneuro.2020.05.001_bib0036","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0269881117722987","article-title":"Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment","volume":"31","author":"Reynolds","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2020.05.001_bib0037","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2020.05.001_bib0038","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.euroneuro.2020.05.001_bib0039","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2020.05.001_bib0040","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","article-title":"Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicenter drug safety surveillance project","volume":"21","author":"St\u00fcbner","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.05.001_bib0041","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2014.10.011","article-title":"Weight gain and associated factors in patients using newer antidepressant drugs","volume":"37","author":"Uguz","year":"2015","journal-title":"Gen. Hosp. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20301309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20301309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:54:56Z","timestamp":1760378096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20301309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"alternative-id":["S0924977X20301309"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.05.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe weight gain as an adverse drug reaction of psychotropics: Data from the AMSP project between 2001 and 2016","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}